Good Manufacturing Practice: Manufacturing of a Nerve Agent Antidote Nanoparticle Suspension

• Published in: International journal of toxicology 2013-07, Vol.32 (4_suppl), p.18S-29S
• Main Authors: Clark, Andrew P.-Z., Dixon, Hong, Cantu, Norma L., Cabell, Larry A., McDonough, Joe A.
• Format: Article
• Language: English
• Subjects: Animals; Antidotes - chemistry; Antidotes - pharmacology; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Industry - standards; Drug Stability; Nanoparticles - chemistry; Oximes - chemistry; Oximes - pharmacology; Particle Size; Rabbits; Reproducibility of Results; Suspensions - chemistry
• ISSN: 1091-5818; 1092-874X
• DOI: 10.1177/1091581813490204

We have established a current good manufacturing practice (GMP) manufacturing process to produce a nanoparticle suspension of 1,1′-methylenebis-4-[(hydroxyimino)methyl]pyridinium dimethanesulfonate (MMB4 DMS) in cottonseed oil (CSO) as a nerve agent antidote for a Phase 1 clinical trial. Bis-pyridinium oximes such as MMB4 were previously developed for emergency treatment of organophosphate nerve agent intoxication. Many of these compounds offer efficacy superior to monopyridinium oximes, but they have poor thermal stability due to hydrolytic cleavage in aqueous solution. We previously developed a nonaqueous nanoparticle suspension to improve the hydrothermal stability, termed Enhanced Formulation (EF). An example of this formulation technology is a suspension of MMB4 DMS nanoparticles in CSO. Due to the profound effect of particle size distribution on product quality and performance, particle size must be controlled during the manufacturing process. Therefore, a particle size analysis method for MMB4 DMS in CSO was developed and validated to use in support of good laboratory practice/GMP development and production activities. Manufacturing of EF was accomplished by milling MMB4 DMS with CSO and zirconia beads in an agitator bead mill. The resulting bulk material was filled into 5-mL glass vials at a sterile fill facility and terminally sterilized by gamma irradiation. The clinical lot was tested and released, a Certificate of Analysis was issued, and a 3-year International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) stability study started. The drug product was placed in storage for Phase 1 clinical trial distribution. A dose delivery uniformity study was undertaken to ensure that the correct doses were delivered to the patients in the clinic.